Pelthos Therapeutics’ (PTHS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Pelthos Therapeutics (NYSEAMERICAN:PTHS) in a report published on Thursday,Benzinga reports. HC Wainwright currently has a $60.00 target price on the stock.

PTHS has been the subject of several other reports. Oppenheimer raised their price objective on Pelthos Therapeutics from $57.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday, January 26th. Roth Mkm cut their target price on Pelthos Therapeutics from $57.00 to $55.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Piper Sandler began coverage on Pelthos Therapeutics in a report on Friday, February 27th. They set an “overweight” rating and a $48.00 price target on the stock. Finally, Zacks Research lowered shares of Pelthos Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, January 30th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Pelthos Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.25.

Pelthos Therapeutics Trading Down 9.7%

PTHS opened at $20.74 on Thursday. The stock has a 50-day moving average of $23.28. Pelthos Therapeutics has a 12 month low of $9.00 and a 12 month high of $54.29. The stock has a market capitalization of $67.20 million, a price-to-earnings ratio of -1.00 and a beta of 3.87.

Institutional Trading of Pelthos Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Ikarian Capital LLC boosted its position in shares of Pelthos Therapeutics by 309.5% during the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after buying an additional 193,307 shares during the period. Boothbay Fund Management LLC raised its holdings in shares of Pelthos Therapeutics by 279.8% in the fourth quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after buying an additional 59,435 shares during the period. J. Goldman & Co LP bought a new stake in shares of Pelthos Therapeutics during the 4th quarter worth approximately $2,418,000. Cantor Fitzgerald L. P. bought a new stake in shares of Pelthos Therapeutics during the 4th quarter worth approximately $1,085,000. Finally, Diadema Partners LP boosted its holdings in Pelthos Therapeutics by 138.1% during the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after acquiring an additional 14,502 shares during the period. Institutional investors own 77.96% of the company’s stock.

Pelthos Therapeutics News Roundup

Here are the key news stories impacting Pelthos Therapeutics this week:

• Positive Sentiment: Oppenheimer raised its price target to $62 and kept an “outperform” rating, signaling continued institutional conviction in multi-year upside. Article Title
• Positive Sentiment: HC Wainwright increased long-term EPS forecasts materially for FY2028–FY2030 (FY2028 to $10.86, FY2029 to $15.42, FY2030 to $18.79), implying analysts expect the company’s pipeline or commercialization prospects to deliver significant profit expansion several years out. Article Title
• Neutral Sentiment: HC Wainwright reiterated a “Buy” rating with a $60 target — the firm remains constructive, but the rating alone is not offsetting concerns about near-term profitability revisions. Article Title
• Negative Sentiment: HC Wainwright sharply lowered near-term EPS estimates for 2026 across multiple quarters (Q1-Q4 2026) and cut FY2026 from about ($6.31) to ($14.39) — this large downgrade increases short-term execution and funding risk and is the primary likely catalyst for the stock’s decline today. Article Title

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).